TY - JOUR T1 - Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents. AU - Jouanne,Marie, AU - Rault,Sylvain, AU - Voisin-Chiret,Anne-Sophie, Y1 - 2017/07/29/ PY - 2017/07/12/received PY - 2017/07/27/revised PY - 2017/07/28/accepted PY - 2017/8/12/pubmed PY - 2017/11/1/medline PY - 2017/8/12/entrez KW - Aggregation KW - Alzheimer's disease KW - Tau protein KW - Therapeutic agents SP - 153 EP - 167 JF - European journal of medicinal chemistry JO - Eur J Med Chem VL - 139 N2 - Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunction and the accumulation of two proteins which are, respectively, the beta-amyloid peptide and the tau protein. The process that leads these two proteins to aggregate is complex and is the subject of current studies. After a brief description of the aggregation mechanisms, we will provide an overview of new therapeutic agents targeting the different dysfunctions and toxic species found during aggregation. SN - 1768-3254 UR - https://www.unboundmedicine.com/medline/citation/28800454/Tau_protein_aggregation_in_Alzheimer's_disease:_An_attractive_target_for_the_development_of_novel_therapeutic_agents_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0223-5234(17)30592-5 DB - PRIME DP - Unbound Medicine ER -